StimLabs, a regenerative medicine company, recently announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for Geistlich’s DermaForm, a Collagen Scaffold Particulate, that is an extracellular matrix wound care product designed to protect and manage of a variety of both chronic and acute wounds.
The clearance of DermaForm is an important portfolio milestone for StimLabs, further strengthening its range of innovative solutions available to clinicians treating complex and chronic wounds.
“DermaForm represents an ongoing commitment to innovation and our ability to bring meaningful products to market. With FDA clearance in place, we are excited to support patient care with a unique solution,” said Tom Dion, executive vice president & chief commercial officer at StimLabs.
“By leveraging our research innovation with StimLabs’ commercial strength, this partnership is poised to set new standards in regenerative medicine,” said David Wemans, vice president regenerative technologies at Geistlich.
Through its collaboration with Geistlich, StimLabs has strengthened its portfolio with DermaForm. Together, the companies are dedicated to offering advanced solutions that enhance outcomes and improve the quality of life for patients with complex wounds.
